Entera Bio Ltd. (ENTX)

Entera Bio Ltd. (ENTX) Healthcare & Pipeline Overview

Entera Bio Ltd., an Israeli clinical-stage biopharmaceutical company, specializes in oral delivery of large molecule therapeutics, addressing unmet needs in hypoparathyroidism and osteoporosis. Its lead candidates, EB612 and EB613, are undergoing clinical trials, positioning the company in the competitive biotechnology landscape with a focus on innovative drug delivery.

What Is the Investment Thesis for ENTX?

Entera Bio presents a compelling, albeit high-risk, investment thesis centered on its innovative oral drug delivery technology for large molecules. The primary value driver is the successful clinical development and commercialization of EB612 for hypoparathyroidism and EB613 for osteoporosis and non-union fractures. Positive Phase II trial results for EB612 could serve as a significant catalyst, potentially leading to partnerships or acquisition interest. However, the company's limited financial resources and the inherent risks associated with clinical-stage drug development are significant concerns. Successful completion of ongoing clinical trials and securing additional funding are critical for realizing the company's potential. The company's market capitalization of $81.78M reflects both the potential upside and the substantial risks involved.

Based on FMP financials and quantitative analysis

ENTX Key Highlights

• EB612 is in Phase II clinical trials for hypoparathyroidism, representing a key milestone in its development.
• EB613 has completed Phase II clinical trials for osteoporosis, indicating potential efficacy and safety.
• Collaboration with Amgen Inc. provides validation of Entera Bio's technology and potential for future partnerships.
• Focus on oral delivery of large molecules addresses a significant unmet need in the biologics market.
• Market capitalization of $81.78M reflects the company's early stage and associated risks.

Who Are ENTX's Competitors?

ENTX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are ENTX's Key Strengths?

• Proprietary oral drug delivery technology.
• Clinical-stage product candidates.
• Collaboration with Amgen Inc.
• Experienced management team.

What Are ENTX's Weaknesses?

• Limited financial resources.
• Dependence on clinical trial success.
• High regulatory hurdles.
• Small number of employees.

What Could Drive ENTX Stock Higher?

• Phase II clinical trial results for EB612 in hypoparathyroidism.
• Phase I clinical trial results for EB613 in non-union fractures.
• Potential for new partnerships or licensing agreements.
• Continued progress in research and development of oral biologics.

What Are the Key Risks for ENTX?

• Negative return on equity (-88.0%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Failure to obtain regulatory approval for EB612 or EB613.
• Unfavorable clinical trial results.
• Competition from established pharmaceutical companies.
• Limited financial resources.
• Changes in the regulatory landscape.

What Are the Growth Opportunities for ENTX?

• Expansion into New Therapeutic Areas: Entera Bio has the opportunity to leverage its oral drug delivery platform to develop therapies for other diseases beyond hypoparathyroidism, osteoporosis, and non-union fractures. This could involve targeting other endocrine disorders, inflammatory conditions, or even cancer. The market for novel drug delivery systems is estimated to reach $80 billion by 2030, providing a substantial opportunity for Entera Bio to diversify its pipeline and revenue streams.
• Strategic Partnerships and Licensing Agreements: Entera Bio can pursue additional partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Collaborations can provide access to funding, expertise, and established distribution networks. The ongoing collaboration with Amgen serves as a model for future partnerships, potentially generating significant upfront payments, milestone payments, and royalties.
• Geographic Expansion: Entera Bio can expand its clinical trials and commercialization efforts beyond Israel and the United States. Europe and Asia represent significant markets for its product candidates, particularly in countries with aging populations and high prevalence of osteoporosis. Entering new geographic markets requires navigating different regulatory requirements and establishing local partnerships.
• Advancement of EB613 for Non-Union Fractures: The successful development and commercialization of EB613 for non-union fractures represents a significant growth opportunity. Non-union fractures are a challenging clinical problem with limited treatment options. Positive Phase I trial results could accelerate the development pathway and attract interest from orthopedic surgeons and hospitals. The market for bone healing therapies is estimated to reach $4 billion by 2028.
• Development of Next-Generation Oral Biologics: Entera Bio can invest in research and development to improve its oral drug delivery platform and develop next-generation biologics with enhanced bioavailability and efficacy. This could involve exploring new excipients, formulations, or delivery devices. Staying at the forefront of innovation is crucial for maintaining a competitive advantage in the rapidly evolving biotechnology industry.

What Opportunities Does ENTX Have?

• Expansion into new therapeutic areas.
• Strategic partnerships and licensing agreements.
• Geographic expansion.
• Development of next-generation oral biologics.

What Threats Does ENTX Face?

• Competition from established pharmaceutical companies.
• Failure to obtain regulatory approval.
• Unfavorable clinical trial results.
• Changes in the regulatory landscape.

What Are ENTX's Competitive Advantages?

• Proprietary oral drug delivery technology for large molecules.
• Clinical-stage product candidates with demonstrated efficacy in early trials.
• Collaboration with Amgen Inc. provides validation and access to resources.
• Focus on niche markets with high unmet needs.

What Does ENTX Do?

Entera Bio Ltd., established in 2009 and headquartered in Jerusalem, Israel, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing orally delivered large molecule therapeutics. The company's mission is to address unmet medical needs by creating patient-friendly alternatives to injectable biologics. Its lead product candidate, EB612, is currently in Phase II clinical trials for the treatment of hypoparathyroidism, a condition characterized by insufficient parathyroid hormone production. Another key asset, EB613, has completed Phase II clinical trials for osteoporosis and is in Phase I trials for non-union fractures, aiming to improve bone healing. Entera Bio's technology seeks to transform the delivery of biologics, potentially enhancing patient compliance and convenience. The company also has a research collaboration and license agreement with Amgen Inc., focusing on the discovery and development of clinical candidates for inflammatory diseases and other serious illnesses. This collaboration underscores Entera Bio's innovative approach and potential within the biotechnology sector.

What Products and Services Does ENTX Offer?

• Develop orally delivered large molecule therapeutics.
• Focus on unmet medical needs in endocrinology and bone health.
• Conduct clinical trials to evaluate the safety and efficacy of its product candidates.
• Seek regulatory approval from the FDA and other health authorities.
• Establish partnerships with pharmaceutical companies for commercialization.
• Research and develop new drug delivery technologies.

How Does ENTX Make Money?

• Develop and out-license or sell orally delivered therapeutics.
• Generate revenue through research collaborations and licensing agreements.
• Potentially generate revenue through direct sales of approved products.
• Focus on developing therapies for niche markets with high unmet needs.

What Industry Does ENTX Operate In?

Entera Bio operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for oral biologics is growing, driven by the desire for more convenient and patient-friendly drug delivery methods. Key competitors include companies developing alternative delivery systems for large molecule therapeutics. The success of Entera Bio depends on its ability to navigate the complex regulatory landscape, secure funding, and demonstrate the clinical efficacy and safety of its product candidates. The biotechnology industry is projected to continue its growth trajectory, fueled by advancements in drug discovery and personalized medicine.

Who Are ENTX's Key Customers?

• Patients with hypoparathyroidism.
• Patients with osteoporosis.
• Patients with non-union fractures.
• Pharmaceutical companies seeking novel drug delivery technologies.

F-Score 1/9Financial Health

Entera Bio Ltd.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 4.85 places it in the safe zone, indicating low near-term bankruptcy risk.

ROE -88%Key Financial Metrics

Return on equity for Entera Bio Ltd. stands at -88.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -94.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.93 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -14.6%, the inverse of the P/E and a quick read on earnings relative to price.

Entera Bio Ltd. (ENTX) Valuation Context

Valued at $81.78M, ENTX is classified as a micro-cap stock. Relative to its peer group, ENTX's quantitative score of 45/100 is below the peer average of 76/100.

FY2026 estForward Outlook

Wall Street analysts project Entera Bio Ltd. revenue of about $54.6M for fiscal 2026, with EPS near $-0.34.

ENTX Financials

ENTX Latest News

ENTX Analyst Consensus

ENTX MoonshotScore

What Investors Ask About Entera Bio Ltd. (ENTX) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources